The Centers for Disease Control and Prevention says one of the test reagents will likely need to be remanufactured in its labs.
The agency aims to aid adoption of NGS within public health labs, which have significantly increased their use of the technology in recent years.
The EUA allows the test to be used at all CDC-qualified labs in the US on patients who meet CDC criteria for testing for the coronavirus.
If granted, emergency use authorization is anticipated to help roll out standardized, consistent 2019-nCoV testing to public health labs in the US.
The agency plans to make test kits available to state and international partners in the next two weeks. It also provided updated information about the virus.
Mere weeks after the 2019-nCoV sequence was released, firms, agencies, and research groups have already created PCR-based tests.
New funding may help improve stalled HIV interventions, in part, by spurring on diagnostic testing access and initiatives.
Apatagen is developing the aptamer-based test to diagnose human carriers of pork tapeworm and prevent neurocysticercosis, which causes adult-onset epilepsy.
The study, sponsored by the US Centers for Disease Control and Prevention, focused on men who have sex with men and members of their social networks.
The company's Liaison XL Zika assay previously received Emergency Use Authorization from the FDA in 2017.